These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 21784738

  • 1. GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study.
    Kol S, Humaidan P, Itskovitz-Eldor J.
    Hum Reprod; 2011 Oct; 26(10):2874-7. PubMed ID: 21784738
    [Abstract] [Full Text] [Related]

  • 2. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY, Elbaek HO, Alsbjerg B, Laursen RJ, Povlsen BB, Thomsen L, Humaidan P.
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT, Ohlinger R.
    Eur J Obstet Gynecol Reprod Biol; 2006 May 01; 126(1):87-92. PubMed ID: 16377065
    [Abstract] [Full Text] [Related]

  • 4. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C.
    Fertil Steril; 2010 Feb 01; 93(3):847-54. PubMed ID: 19200959
    [Abstract] [Full Text] [Related]

  • 5. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, Papanikolaou EG, Andersen CY.
    Hum Reprod; 2013 Sep 01; 28(9):2511-21. PubMed ID: 23753114
    [Abstract] [Full Text] [Related]

  • 6. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM, Polyzos NP, van Vaerenbergh I, Bourgain C, Blockeel C, Alsbjerg B, Papanikolaou EG, Humaidan P.
    Fertil Steril; 2013 Sep 01; 100(3):742-7. PubMed ID: 23806846
    [Abstract] [Full Text] [Related]

  • 7. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep 01; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 8. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S, Blockeel C, Tremellen KP, Fleming R, Tournaye H, Humaidan P, Nelson SM.
    Hum Reprod; 2013 Sep 01; 28(9):2529-36. PubMed ID: 23873146
    [Abstract] [Full Text] [Related]

  • 9. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders.
    Datta AK, Eapen A, Birch H, Kurinchi-Selvan A, Lockwood G.
    Reprod Biomed Online; 2014 Nov 01; 29(5):552-8. PubMed ID: 25246126
    [Abstract] [Full Text] [Related]

  • 10. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T.
    Hum Reprod; 2006 May 01; 21(5):1260-5. PubMed ID: 16439507
    [Abstract] [Full Text] [Related]

  • 11. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
    Kolibianakis EM, Schultze-Mosgau A, Schroer A, van Steirteghem A, Devroey P, Diedrich K, Griesinger G.
    Hum Reprod; 2005 Oct 01; 20(10):2887-92. PubMed ID: 15979994
    [Abstract] [Full Text] [Related]

  • 12. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, Andersen CY.
    Hum Reprod; 2005 May 01; 20(5):1213-20. PubMed ID: 15760966
    [Abstract] [Full Text] [Related]

  • 13. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
    Haas J, Kedem A, Machtinger R, Dar S, Hourvitz A, Yerushalmi G, Orvieto R.
    J Ovarian Res; 2014 Apr 03; 7():35. PubMed ID: 24694069
    [Abstract] [Full Text] [Related]

  • 14. Day two post retrieval 1500 IUI hCG bolus, progesterone-free luteal support post GnRH agonist trigger - a proof of concept study.
    Vanetik S, Segal L, Breizman T, Kol S.
    Gynecol Endocrinol; 2018 Feb 03; 34(2):132-135. PubMed ID: 28933569
    [Abstract] [Full Text] [Related]

  • 15. GnRHa to trigger final oocyte maturation: a time to reconsider.
    Humaidan P, Papanikolaou EG, Tarlatzis BC.
    Hum Reprod; 2009 Oct 03; 24(10):2389-94. PubMed ID: 19608565
    [Abstract] [Full Text] [Related]

  • 16. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
    Radesic B, Tremellen K.
    Hum Reprod; 2011 Dec 03; 26(12):3437-42. PubMed ID: 21997895
    [Abstract] [Full Text] [Related]

  • 17. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK, Schultze-Mosgau A, Cordes T, Diedrich K, Griesinger G.
    Arch Gynecol Obstet; 2013 Oct 03; 288(4):901-4. PubMed ID: 23545834
    [Abstract] [Full Text] [Related]

  • 18. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I, Mizrachi Y, Karfunkel-Doron D, Omer Y, Sheena L, Carmon N, Ben-David G.
    Fertil Steril; 2016 Aug 03; 106(2):330-3. PubMed ID: 27114332
    [Abstract] [Full Text] [Related]

  • 19. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R.
    J Ovarian Res; 2015 Nov 04; 8():69. PubMed ID: 26536862
    [Abstract] [Full Text] [Related]

  • 20. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial.
    Fatemi HM, Kolibianakis EM, Camus M, Tournaye H, Donoso P, Papanikolaou E, Devroey P.
    Hum Reprod; 2006 Oct 04; 21(10):2628-32. PubMed ID: 16857887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.